Generation of ligand conformations in continuum solvent consistent with protein active site topology: application to thrombin.

Using the crystal structure of an inhibitor complexed with the serine protease thrombin (PDB code ) and the functional group definitions contained within the Catalyst software, a representation of the enzyme's active site was produced (structure-based pharmacophore model). A training set of 16 homologous non-peptide inhibitors whose conformations had been generated in continuum solvent (MacroModel) and clustered into conformational families (XCluster) was regressed against this pharmacophore so as to obtain a 3D-QSAR model. To test the robustness of the resulting QSAR model, the synthesis of a series of non-peptide thrombin inhibitors based on arylsuphonyl derivatives of an aminophenol ring linked to a pyridyl-based S1 binding group was undertaken. These compounds served as a test set (20-24). The crystal structure for the novel symmetrical disulfonyl compound 24, in complex with thrombin, has been solved. Its calculated binding mode is in general agreement with the crystallographically observed one, and the predicted K(i) value is in close accord with the experimental value.

[1]  Peter D. J. Grootenhuis,et al.  Comparative molecular field analysis and energy interaction studies of thrombin-inhibitor complexes , 1999, J. Comput. Aided Mol. Des..

[2]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[3]  L. Bladh,et al.  Pharmacophores incorporating numerous excluded volumes defined by X-ray crystallographic structure in three-dimensional database searching: application to the thyroid hormone receptor. , 1998, Journal of medicinal chemistry.

[4]  C L Brooks,et al.  Do active site conformations of small ligands correspond to low free-energy solution structures? , 1998, Journal of computer-aided molecular design.

[5]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[6]  F. A. Neugebauer,et al.  Electrochemical oxidation and structural changes of 5,6-dihydrobenzo[c]cinnolines , 1996 .

[7]  Jeremy C. Smith,et al.  Can the calculation of ligand binding free energies be improved with continuum solvent electrostatics and an ideal‐gas entropy correction? , 2002, J. Comput. Chem..

[8]  P A Greenidge,et al.  A comparison of methods for pharmacophore generation with the catalyst software and their use for 3D-QSAR: application to a set of 4-aminopyridine thrombin inhibitors. , 2001, Mini reviews in medicinal chemistry.

[9]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[10]  Richard A. Engh,et al.  DERIVATIVES OF 4-AMINO-PYRIDINE AS SELECTIVE THROMBIN INHIBITORS , 1997 .

[11]  A. Olson,et al.  Revisiting Catalysis by Chymotrypsin Family Serine Proteases Using Peptide Substrates and Inhibitors with Unnatural Main Chains* , 1999, The Journal of Biological Chemistry.

[12]  E. Di Cera,et al.  Identification of residues linked to the slow-->fast transition of thrombin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. G. Goodwin,et al.  Surface concentrations and residence times of intermediates on samarium oxide during the oxidative coupling of methane , 1990 .

[14]  Christopher W. Murray,et al.  The sensitivity of the results of molecular docking to induced fit effects: Application to thrombin, thermolysin and neuraminidase , 1999, J. Comput. Aided Mol. Des..

[15]  Vladimir G. Tsirelson,et al.  Multipole analysis of the electron density in triphylite, LiFePO4, using X‐ray diffraction data , 1993 .

[16]  S. Rutella,et al.  Binding of Thrombin to Glycoprotein Ib Accelerates the Hydrolysis of Par-1 on Intact Platelets* , 2001, The Journal of Biological Chemistry.

[17]  H. Nar,et al.  Structure-based design of novel potent nonpeptide thrombin inhibitors. , 2002, Journal of medicinal chemistry.

[18]  E. Skordalakes,et al.  Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. , 1995, Journal of medicinal chemistry.

[19]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[20]  L. Kuhn,et al.  Cluster analysis of consensus water sites in thrombin and trypsin shows conservation between serine proteases and contributions to ligand specificity , 1998, Protein science : a publication of the Protein Society.

[21]  Jonas Boström,et al.  Conformational energy penalties of protein-bound ligands , 1998, J. Comput. Aided Mol. Des..

[22]  R. Kinne,et al.  Probing the conformation of the sugar transport inhibitor phlorizin by 2D-NMR, molecular dynamics studies, and pharmacophore analysis. , 2000, Journal of medicinal chemistry.

[23]  J. Ponder,et al.  An efficient newton‐like method for molecular mechanics energy minimization of large molecules , 1987 .

[24]  J. Rizo,et al.  Consensus bioactive conformation of cyclic GnRH antagonists defined by NMR and molecular modeling. , 2000, Journal of medicinal chemistry.

[25]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[26]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[27]  Peter S. Shenkin,et al.  Cluster analysis of molecular conformations , 1994, J. Comput. Chem..

[28]  G. Chang,et al.  Macromodel—an integrated software system for modeling organic and bioorganic molecules using molecular mechanics , 1990 .